UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000031885
Receipt number R000036376
Scientific Title Effectiveness and cost-effectiveness of mindfulness-based programs for improving the subjective well-being of healthy individuals: a randomized wait-list controlled trial.
Date of disclosure of the study information 2018/03/27
Last modified on 2021/09/27 16:15:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effectiveness and cost-effectiveness of mindfulness-based programs for improving the subjective well-being of healthy individuals: a randomized wait-list controlled trial.

Acronym

Effectiveness and cost-effectiveness of mindfulness-based programs for improving the subjective well-being of healthy individuals: a randomized wait-list controlled trial.

Scientific Title

Effectiveness and cost-effectiveness of mindfulness-based programs for improving the subjective well-being of healthy individuals: a randomized wait-list controlled trial.

Scientific Title:Acronym

Effectiveness and cost-effectiveness of mindfulness-based programs for improving the subjective well-being of healthy individuals: a randomized wait-list controlled trial.

Region

Japan


Condition

Condition

healthy individuals

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate whether or not mindfulness-based programs is effective and cost-effective for improving the subjective well-being of healthy individuals by a randomized wait-list controlled trial.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase III


Assessment

Primary outcomes

The difference in mean change scores at 8 weeks from baseline on the Satisfaction With Life Scale between groups.

Key secondary outcomes

(1)The difference in mean change scores at 4,8,16 weeks from baseline on FS, SPANE, RSES, FFMQ, the Connor Davidson Resilience Scale, SCS, QIDS, GAD7, PSS, HPQ Short Form Japanese final, MAIA, EQ-5D-5L between groups. With respect to cost-effective analysis, effectiveness and cost will be evaluated by QALY or other clinical scale, and the cost for intervention respectively.
(2)The difference in mean change scores at 4,16 weeks from baseline on the Satisfaction With Life scale between groups.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Behavior,custom

Interventions/Control_1

8 weekly sessions based on Mindfulness-based program

Interventions/Control_2

no interventions (waiting-list)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

/No past history of mental disorders or with history but have been remitted longer than 2 years
/Score of SWLS is 24 or lower
/Able to consent in writing

Key exclusion criteria

/Difficult to follow up for 4 months after start of intervention
/Past history of mindfulness based intervention
/Severe physical conditions

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Mitsuhiro
Middle name
Last name Sado

Organization

Keio University School of Medicine

Division name

Department of Neuropsychiatry

Zip code

160-8582

Address

35 Shinanomachi, Shinjuku-ku, Tokyo

TEL

+81-(0)3-5363-3971

Email

mitsusado@keio.jp


Public contact

Name of contact person

1st name Mitsuhiro
Middle name
Last name Sado

Organization

Keio University School of Medicine

Division name

Department of Neuropsychiatry

Zip code

160-8582

Address

35 Shinanomachi, Shinjuku-ku, Tokyo

TEL

+81-(0)3-5363-3971

Homepage URL


Email

mitsusado@keio.jp


Sponsor or person

Institute

Keio University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Ministry of Education, Culture, Sports, Science and Technology

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Keio University School of Medicine

Address

35 Shinanomachi, Shinjuku-ku, Tokyo

Tel

+81-(0)3-3353-1211

Email

med-rinri-jimu@adst.keio.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 03 Month 27 Day


Related information

URL releasing protocol

https://pubmed.ncbi.nlm.nih.gov/32005642/

Publication of results

Partially published


Result

URL related to results and publications

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441176/

Number of participants that the trial has enrolled

50

Results

Differences between the MBCT group and the control group regarding mean change scores for SWLS scores were significant at 8 weeks. The MBCT effect was even stronger at the 2-month follow-up.

Results date posted

2021 Year 09 Month 27 Day

Results Delayed


Results Delay Reason

Due to the delay in analysis.

Date of the first journal publication of results


Baseline Characteristics

The average age was 46.8years, and 78.0% were female. All participants were employed or were students or homemakers, and the average household income was relatively high. No significant differences between the groups were observed with respect to sociodemographic status. In terms of the clinical measures, there were no significant differences, except for SPANE-P, SPANE-B and MAIA Not-Worrying.

Participant flow

Beginning in July 2018, 90 participants were screened. Fifty participants (55.6%) met the inclusion criteria and were randomly allocated to the MBCT group (n = 25) or the waiting-list control group (n = 25). Two participants in each group dropped out.

Adverse events

No serious adverse events were observed over the study period.

Outcome measures

SWLS
FS
SPANE
RSES
FFMQ
CDRISC
SCS
QIDS
GAD7
PSS
WHO-HPQ
MAIA
EQ-5D-5L

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2018 Year 03 Month 16 Day

Date of IRB

2018 Year 03 Month 27 Day

Anticipated trial start date

2018 Year 05 Month 01 Day

Last follow-up date

2019 Year 09 Month 30 Day

Date of closure to data entry

2019 Year 10 Month 30 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 03 Month 25 Day

Last modified on

2021 Year 09 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036376


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name